Drug Trial Radar · NCT04241068
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,696
Actual
Start
Mar 2, 2020
Primary completion
Jul 22, 2024
Study completion Jul 22, 2024
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jan 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).
Conditions
- Alzheimer's Disease
Interventions
AducanumabDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Treatment Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: From the first dose of study drug to end of follow-up (up to Week 118)
- Core Treatment Period: Number of Participants With AEs Leading to Treatment Discontinuation (TD) and Study Withdrawal (SW)Time frame: From the first dose of study drug to end of follow-up (up to Week 118)
- Core Treatment Period: Number of Participants With Amyloid-Related Imaging Abnormality-Edema (ARIA-E)Time frame: Up to Week 118
- Core Treatment Period: Number of Participants With Amyloid-Related Imaging Abnormality- Hemorrhage or Superficial Siderosis (ARIA-H)Time frame: Up to Week 118
- Core Treatment Period: Number of Participants With Positive Antidrug Antibodies (ADAs) in SerumTime frame: Up to Week 102
Locations
297 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Banner Alzheimer's Institute
Phoenix, Arizona
Dignity Health
Phoenix, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
Center for Neurosciences
Tucson, Arizona
Neurology Center of North Orange County
Fullerton, California
UCI MIND
Irvine, California
University of California San Diego Medical Center
La Jolla, California
Senior Clinical Trials, Inc.
Laguna Hills, California
USC Keck School of Medicine
Los Angeles, California
Mary S. Easton Center for Alzheimer's Disease Research, UCLA
Los Angeles, California
Pacific Neuroscience Medical Group
Oxnard, California
Stanford Hospital and Clinics
Palo Alto, California
Anderson Clinical Research
Redlands, California
Pacific Research Network, Inc
San Diego, California
UCSF - Memory and Aging Center
San Francisco, California
Syrentis Clinical Research
Santa Ana, California
California Neuroscience Research Medical Group Inc.
Sherman Oaks, California
University of Colorado Denver
Aurora, Colorado
IMMUNOe International Research Centers
Centennial, Colorado
Yale University
Fairfield, Connecticut
Invicro
New Haven, Connecticut
Yale University School Of Medicine
New Haven, Connecticut
Research Center for Clinical Studies, Inc.
Norwalk, Connecticut
Georgetown University Clinical Research Unit (CRU)
Washington D.C., District of Columbia
JEM Research
Atlantis, Florida
Bradenton Research Center, Inc
Bradenton, Florida
Brain Matters Research
Delray Beach, Florida
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Mayo Clinic in Florida
Jacksonville, Florida
University of Miami
Miami, Florida
Miami Jewish Health System, Inc
Miami, Florida
Renstar Medical Research
Ocala, Florida
Accelerated Enrollment Solutions (AES)
Orlando, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Accelerated Enrollment Solutions (AES)
Orlando, Florida
Palm Beach Neurological Center
Palm Beach Gardens, Florida
Quantum Laboratories Inc.
Pompano Beach, Florida
Showing 40 of 297 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.